Yuhan Corporation (000100) Stock Overview

Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; and Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury. The company also provides ETC products, such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems, as well as anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. In addition, it offers over-the-counter (OTC) products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; veterinary drugs; and household and healthcare products. Further, the company provides dental care products. Additionally, it manufactures and sells animal medicines and feeds; and provides contract manufacturing services. The company was founded in 1926 and is headquartered in Seoul, South Korea.